Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.33 |
| ▸ | GUSB | P08236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vp-14637 SCHEMBL29351615 | 1.00 | GAA (0.45) | GAAKDM4EHPGDGFERALDH1A1 | |
| Vp-14637 SCHEMBL20741449 | 1.00 | GAA (0.45) | GAAKDM4EHPGDGFERALDH1A1 | |
| SCHEMBL7070861 | 0.91 | ALDH1A1 (0.45) | GAAKDM4EHPGDGFERALDH1A1 | |
| SCHEMBL10106495 | 0.91 | GAA (0.45) | GAAKDM4EHPGDGFERALDH1A1 | |
| SCHEMBL22788662 | 0.89 | KDM4E (0.49) | GAAKDM4EHPGDGFERALDH1A1 | |
| SCHEMBL7067443 | 0.89 | ALDH1A1 (0.45) | GAAKDM4EHPGDGFERALDH1A1 | |
| SCHEMBL7068147 | 0.88 | ALDH1A1 (0.41) | GAAKDM4EHPGDGFERALDH1A1 | |
| SCHEMBL21117062 | 0.86 | GAA (0.38) | GAAKDM4EHPGDGFERALDH1A1 | |
| SCHEMBL642652 | 0.86 | GAA (0.43) | GAAKDM4EHPGDGFERALDH1A1 | |
| SCHEMBL6215111 | 0.86 | GAA (0.40) | GAAKDM4EHPGDGFERALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066065-A1 | PLATELET DERIVATIVES FOR TREATING COAGULOPATHY | CELLPHIRE, INC. (US) | 2024-02-29 | — | — | US | claimed |
| US-20220279777-A1 | FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR TREATING ANTICOAGULANT-INDUCED COAGULOPATHY | CELLPHIRE INC. (US) | 2022-09-08 | — | — | US | claimed |
| WO-2022178191-A1 | FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR TREATING ANTICOAGULANT-INDUCED COAGULOPATHY | CELLPHIRE, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| EP-4013432-A1 | THROMBOSOMES AS AN ANTICOAGULANT REVERSAL AGENT | Cellphire Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250177450-A1 | METHODS FOR ADMINISTERING FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS TO SUBJECTS TREATED WITH A FACTOR XI INHIBITOR | CELLPHIRE, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250073271-A1 | METHODS OF ADMINISTERING PLATELET DERIVATIVE COMPOSITIONS TO REDUCE BLEEDING IN SUBJECTS REFRACTORY TO PLATELET TRANSFUSION | CELLPHIRE, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-20250064856-A1 | METHODS FOR ADMINISTERING PLATELET DERIVATIVE COMPOSITIONS TO SUBJECTS AFFLICTED WITH HERMANSKY PUDLAK SYNDROME OR BERNARD SOULIER SYNDROME | CELLPHIRE, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| WO-2024229305-A1 | PLATELET DERIVATIVE COMPOSITIONS FOR USE IN CONTROLLING BLEEDING IN A SUBJECT | CELLPHIRE, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| US-20240307453-A1 | METHODS FOR CONTROLLING BLEEDING IN A SUBJECT AFFLICTED WITH HERMANSKY PUDLAK SYNDROME USING PLATELET DERIVATIVE COMPOSITIONS | CELLPHIRE, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| WO-2024192173-A1 | HLA-CHARACTERIZED PLATELET DERIVATIVE COMPOSITIONS, AND METHODS OF MAKING, SELECTING AND USING SUCH COMPOSITIONS | CELLPHIRE, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20170100385-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-04-13 | — | — | US | disclosed |
| US-20170100385-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-04-13 | — | — | US | disclosed |
| US-9504672-B2 | Compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504672-B2 | Compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150209328-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MICRODOSE THERAPEUTX, INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150209328-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MICRODOSE THERAPEUTX, INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-9040569-B2 | Compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040569-B2 | Compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX (US) | 2015-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209328-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MDN1, PRTN3, MBTD1 | GAA 2624/4885KDM4E 4771/4885HPGD 2125/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | GAA 269/4885KDM4E 935/4885HPGD 3521/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | GAA 269/4885KDM4E 935/4885HPGD 3521/4885 |
| US-20170100385-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | DDOST, DHX30, DDX5 | GAA 123/4885KDM4E 4515/4885HPGD 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.